Prevalence and associated risk factors of latent tuberculosis infection in a Spanish prison

López de Goicoechea-Saiz ME\textsuperscript{1}, Sternberg F\textsuperscript{2}, Portilla-Sogorb J\textsuperscript{3}

\textsuperscript{1}Facultativo de Sanidad Penitenciaria. Centro Penitenciario Madrid VI. Madrid (España)
\textsuperscript{2}Subdirector Médico. Centro Penitenciario Madrid VI. Madrid (España)
\textsuperscript{3}Jefe de Servicio de Medicina Interna. Hospital General Universitario de Alicante. Alicante (España)

ABSTRACT

Aim: To determine the prevalence of latent tuberculosis infection (LTI) in a Spanish prison, analyze the main sociodemographic and clinical variables associated with this condition and estimate the percentage of individuals with LTI who have received chemoprophylactic treatment.

Materials and methods: Cross-sectional study including inmates hosted in the Madrid VI Prison on 16/07/2016. Exclusion criteria: history of tuberculosis; non-updated tuberculin test according to the Tuberculosis Prevention and Control Program in Prisons protocol. Information of the variables was collected from SANIT and SIP programs, and by checking the clinical records of inmates. Description of the participant population and comparison between the frequency of distribution of the independent variables in LTI present and absent groups were performed, the last calculating the $p$ value with $\chi^2$ and Mann-Whitney U tests. Bivariate and multivariate analysis have been carried out with a logistic regression model.

Results: 936 individuals have been included. The prevalence of LTI in prison is 54.6%. This condition has been linked to the sociodemographic variables age, sex and nationality of origin, being age the one that has shown the strongest association. Among the other factors analyzed, only HCV infection behaves as a predictor of LTI. 30.3% of the individuals with LTI have completed or are receiving chemoprophylactic treatment in the moment of the study.

Discussion: LTI prevalence is high in the Spanish current prison population. The results of the study emphasize the relevance of the LTI screening in the prison setting, specially among high risk groups, and point out the need of a greater effort in the indication and completion of the chemoprophylactic treatment.

Keywords: latent tuberculosis; prevalence; risk factors; prisons; \textit{Mycobacterium tuberculosis}; tuberculin; Public Health; Spain.

INTRODUCTION

Today tuberculosis (TB) is considered a major public health issue. According to the 2017 WHO Global Tuberculosis report, in 2016 1.3 million people died because of this condition. The estimated incidence of tuberculosis worldwide for that same year was 10.4 million cases, of which almost 4.700 were reported in our country\textsuperscript{1}. Tuberculosis is an infectious disease caused by \textit{Mycobacterium tuberculosis} bacillus. The disease is spread when people who are sick with pulmonary TB (index case) expel bacteria into the air, to other people (contacts), therefore causing TB disease or latent tuberculous infection (LTI)- without clinical or radiologic evidence of active disease\textsuperscript{2}. An estimated third of the world population currently presents LTI\textsuperscript{1} and only between 5 and 10% will develop TB disease during their lifetime, although that proportion can climb up to 30% for patients with HIV\textsuperscript{1,3}.

For the Prisons Department TB is also one of the most significant public health issues due to its higher incidence with regard to the general population\textsuperscript{4,5} and to the fact that imprisonment itself is a risk factor for the development of TB disease\textsuperscript{5,6,7}. In this regard, since 1991 the Department has implemented TB prevention and control programs which have been successful in reducing the incidence of the disease among the imprisoned population in our country\textsuperscript{8}. These programs focus on the early the early diagnosis and
directly observed therapy of new cases, the study of contacts and the detection and prioritization of treatment for LTI cases depending on concurrent risk factors.

Latency is one of the main obstacles in the eradication of TB since most of the cases of active TB are due to the reactivation of latent bacilli, which usually involves individuals with coexisting risk factors. Available evidence suggests that age and comorbidity (such as HIV, rheumatoid arthritis, asthma or chronic kidney disease), are predictors for both LTI and TB disease. However, studies are controversial on whether social factors such as smoking, alcohol abuse and drug use should be considered.

The identification of risk groups has become a challenge and a priority to achieve the control and eradication of the disease. Nevertheless, there are few studies carried out in settings where the incidence is higher such as prisons, and the previously existing data cannot be extrapolated to today’s Spanish inmate population.

This study has a dual objective. On one hand, it intends to estimate the prevalence of LTI in a Spanish type prison (representative of penitentiary facilities built in Spain in the last 25 years) with a urban module structure and a capacity for hosting around 1000 inmates. On the other hand, the study analyses the role of factors traditionally associated to LTI as well as others which can be found among the imprisoned population such as the impact of severe mental illness, being under chronic psychotropic treatment or the inclusion in methadone rehabilitation programmes, which have still not been assessed.

Last, the proportion of LTI patients who have completed or are currently on chemoprophylactic treatment has been estimated.

MATERIAL AND METHODS

Design and subjects of the study

We have carried out a cross-sectional descriptive study in Madrid VI Prison. The target population is that of the correctional facility (Madrid VI). The inclusion criteria was the fact of being registered in this facility on 16/07/2016. 1090 individuals fulfilled this requirement. 154 individuals were excluded from the study: 5 due to a background of TB disease and 149 due to a lack of updated PPD test results according to the protocol of TB Prevention and Control in the Correctional Setting. This protocol establishes, among other recommendations, that PPD test should be repeated every six months in inmates with HIV and every year for HIV-negative patients, provided that there is no previous positive test. The lack of information was due in 34 cases to the refusal of patients to undergo the test, in 69 cases they had already been scheduled for the test but not undergone it yet, and in the remaining 46 because of a delay of the healthcare staff to carry out the test or to transfer the results to the SANIT software.

Variables

Independent variables included in the study were the following: gender (male/female), age classified in 4 groups according to quartiles (under 31/31-38/39-47/over 47), nationality classified in 4 categories (Spain and other developed countries/Latin-America/Africa/Eastern Europe and the Middle East), a background of smoking (yes/no), previous methadone maintenance treatment (yes/no), being under chronic psychotropic treatment (yes/no), HIV infection (yes/no), active or resolved HCV infection (yes/no), severe mental disorder (yes/no) and previously completed or current chemoprophylactic treatment (yes/no). The dependent variable is LTI (present/absent). Variables PPD test result (positive, negative and unavailable) and previous TB disease (yes/no) were used to determine the excluded cases.

LTI was considered for those individuals with positive PPD test, measured as a swollen area (induration) of 5 mm or more or as the appearance of vesicles or necrosis 48-72 hours after the injection, regardless the vaccination status of patients. In all cases, active disease was ruled out. LTI was excluded in those cases without positive criteria after assessing the booster effect and discarding recent infectious processes.

The diagnosis of severe mental disorder was established in those patients with non-organic psychotic disorders and some cases with ongoing personality disorder for over 2 years, who also presented moderate to severe dysfunction in terms of work, social and family performance.

Collection of data and statistical analysis

Data on the variables gender, age and nationality were obtained by means of the SIP software (Prison Information System of restricted access). The information on a background of psychotropic treatment, PPD results, HIV and HCV infections was collected by means of the SANIT software. In order to establish the background of TB disease, smoking, methadone maintenance treatment and previously completed or current chemoprophylaxis, paper medical records were consulted. With regard to the diag-
nosis of severe mental disorder, this was consulted in a computer-based record of the Madrid VI setting itself. The collection of data was carried out by a single investigator.

For the analysis of data, SPSS Statistics 23 programme was used. The description of qualitative variables and the estimation of LTI prevalence are depicted as absolute values and percentages. For the continuous quantitative variable age, the distribution of its values was assessed by means of the Kolmogov-Smirnov test, by considering central trend measures such as the median and inter-quartile ranges (IQR), due to its non-normal distribution. The frequency of distribution of independent variables in the LTI present or absent groups has been analyzed. To verify the differences between both groups p value has been calculated by means of Ji² and Mann-Whitney U tests. Statistical significance was defined for p value of 0.05 or less. The magnitude of the association between different variables and the presence of LTI has been established by means of logistic-regression bivariate and multivariate analysis, therefore considering potential confusing factors. The calculated association measure has been the odds ratio with 95% confidence intervals.

Limitations of the study

The technique used to diagnose TB infection is PPD test, which after the injection of a purified protein derivate (PPD RT-23) shows previous hypersensitivity to that substance. PPD is highly sensitive for individuals with unaltered immune response. However, for HIV-positive patients its sensitivity drops to 70%19,20 which can entail a significant proportion of false-negatives in this population group. Another drawback of PPD test is that proteins are non-specific for Mycobacterium tuberculosis, but common to other non-tuberculous mycobacteria and to Mycobacterium bovis (present in BCG vaccine), which further reduces the specificity of the test and can lead to false-positives.

RESULTS

A total of 936 patients were included in the study, with a mean age of 38 (IQR 31-47), among which 97.4% were males. The vast majority of inmates were originally Spanish (64%), while the remaining 36% were foreign (from 57 different nationalities). 75.4% had a background of smoking, 44.1% were under chronic psychotropic treatment and 13.4% had been on methadone maintenance treatment at some point. The prevalence of HIV infection was 5.6%. 17.4% of the individuals had a background of active or resolved HCV infection and 4.5% had some type of severe mental disorder. In the sample, 511 inmates had a positive PPD test, which entails a prevalence of LTI of 54.6% in this facility. Among patients with LTI, 155 (30.3%) had completed or were currently on chemoprophylactic treatment, while 69.7% were not.

When comparing inmates with and without LTI there are statistically significant differences with regard to the distribution of the following variables: gender (p=0.003), age (p under 0.001), prior or current treatment with methadone (p=0.001), chronic psychotropic treatment (p=0.010) and active or resolved HCV infection (p under 0.001) (see Table 1), unlike the variables smoking (p=0.317), HIV infection (p=0.454) and severe mental disorder (p=0.734). As for the stratified variable nationality, p value was 0.06.

Table 2 depicts the results of bivariate and multivariate analysis, which show the magnitude of the association between the different variables analysed and the presence of LTI. Thus, after adjustment for confounding factors, multivariate analysis shows that there is a higher probability of suffering LTI between male individuals [OR 3.12 (95%CI 1.19-8.16)] and between individuals who are over 38 years old [OR 2.08 (95%CI 1.41-3.05) in the group of 38 to 47 years old with regard to the group of less than 31 years old, and OR 3.90 (95%CI 2.56-5.93) in the group over 47 years old with regard to the same reference group]. As far as nationality is concerned, coming from Eastern Europe or the Middle East was associated with over a two fold increase of the probability of suffering LTI in comparison with coming from Spain or other developed countries [OR 2.13 (95%CI 1.24-3.69)]. This probability is even higher in case of African origin [OR 2.69 (95%CI 1.59-4.55)]. Last, HCV infection was also associated to a higher risk of LTI [OR 1.96 (95%CI 1.22-3.16)].

Multivariate analysis has not shown association between the rest of variables and LTI.

DISCUSSION

This results are coherent with those concluded in the “Multi-centre study on the prevalence of latent TB infection among the population of Spanish prisons”12, based on data collected in 2008 from 341 individuals belonging to 18 Spanish correctional facilities. Therefore, in that study the prevalence of LTI was 50.4% (95%CI 45.0-55.9%), while ours was 54.6%. The
Prevalence and associated risk factors of latent tuberculosis infection in a Spanish prison

The difference between both figures could be due to the fact that the diagnostic criteria for LTI in that study was more restrictive, considering as positive the PPD test when the induration reached 5 mm or more in HIV-positive patients, and 10 mm or more in HIV-negative patients after 48.96 hours of injection, while our study considered a positive result an induration of 5 mm or more regardless the background of HIV infection. The prevalence of LTI was similar to that reported by other previous studies carried out on inmate population in

Table 1. Sociodemographic and clinical features of individuals included in the study with regard to the presence or absence of LTI.

| Variable                                | Absence of LTI N = 425 | Presence of LTI N = 511 | Total N = 936 | p* |
|-----------------------------------------|------------------------|-------------------------|---------------|----|
| Gender [n (%)]                          |                        |                         |               |    |
| Female                                  | 18 (4.2)               | 6 (1.2)                 | 24 (2.6)      | 0.003 |
| Male                                    | 407 (95.8)             | 505 (98.8)              | 912 (97.4)    |    |
| Median age (IQR)                        | 35 (29-43)             | 41 (33-49)              | 38 (31-47)    | <0.001† |
| Age groups [N (%)]                      |                        |                         |               |    |
| <31 years old                           | 152 (35.8)             | 103 (20.2)              | 255 (27.2)    | <0.001 |
| 31-38 years old                         | 112 (26.4)             | 102 (20)                | 214 (22.9)    |    |
| 39-47 years old                         | 101 (23.8)             | 146 (28.6)              | 247 (26.4)    |    |
| >47 years old                           | 60 (14.1)              | 160 (31.3)              | 220 (23.5)    |    |
| Nationality [N (%)]                     |                        |                         |               | 0.064 |
| Spain and developed countries           | 285 (67.1)             | 333 (65.2)              | 618 (66)      |    |
| Latin America                           | 86 (20.2)              | 83 (16.2)               | 169 (18.1)    |    |
| Maghreb and Sub-Saharan Africa          | 28 (6.6)               | 51 (10)                 | 79 (8.4)      |    |
| Eastern Europe and Middle East          | 26 (6.1)               | 44 (8.6)                | 70 (7.5)      |    |
| Smoking [N (%)]                         |                        |                         |               | 0.317 |
| No                                      | 111 (26.1)             | 119 (23.3)              | 230 (24.6)    |    |
| Yes                                     | 314 (73.9)             | 392 (76.7)              | 706 (75.4)    |    |
| On methadone                            |                        |                         |               | 0.001 |
| No                                      | 385 (90.6)             | 426 (83.4)              | 811 (86.6)    |    |
| Yes                                     | 40 (9.4)               | 85 (16.6)               | 125 (13.4)    |    |
| On chronic psychotropic treatment       |                        |                         |               | 0.010 |
| No                                      | 257 (60.5)             | 266 (52.1)              | 523 (55.9)    |    |
| Yes                                     | 168 (39.5)             | 245 (47.9)              | 413 (44.1)    |    |
| HIV infection                           |                        |                         |               | 0.454 |
| No                                      | 404 (95.1)             | 480 (93.9)              | 884 (94.4)    |    |
| Yes                                     | 21 (4.9)               | 31 (6.1)                | 52 (5.6)      |    |
| Active or past HCV infection            |                        |                         |               | <0.001 |
| No                                      | 381 (89.6)             | 392 (76.7)              | 773 (82.6)    |    |
| Yes                                     | 44 (10.4)              | 199 (23.3)              | 163 (17.4)    |    |
| Severe mental disorder                  |                        |                         |               | 0.734 |
| No                                      | 407 (95.8)             | 487 (95.3)              | 894 (95.5)    |    |
| Yes                                     | 18 (4.2)               | 24 (4.7)                | 42 (4.5)      |    |

Note. LTI: latent tuberculosis infection; IQR: Inter-quartile range; HIV: human immunodeficiency virus; HCV: Hepatitis C Virus.

*aChi-square. †Mann-Whitney U.
our country\textsuperscript{21,22}. These data significantly differ from the prevalence of LTI among the general population as noted by the WHO, which estimates it around 30\%\textsuperscript{1}, as well as by a study carried out in the general Spanish population which estimates it around 15\%\textsuperscript{23}.

With regard to LTI-associated factors, multivariate analysis reveals a higher probability of suffering this condition in males. This is coherent with the results of another study carried out in 2003 on the Spanish general population\textsuperscript{23}. However, the result of our study lacks accuracy and it should be noted that only 24 women were included (2.6\%). Thus, this result should be considered with precaution. The association between LTI and the variables age and nationality is also consistent with the previous literature\textsuperscript{12,18}. This can be explained by the fact that the older the individual is, the higher risk of infection due to a more prolonged exposure time. On the other hand, a higher prevalence of LTI is found among individuals who come from countries where TB is still endemic.

Table 2. Factors associated to the presence of LTI: bivariate and multivariate analysis.

| Variable                                      | Crude OR | 95\%CI          | Adjusted OR | 95\%CI          |
|-----------------------------------------------|----------|-----------------|-------------|-----------------|
| Gender                                        |          |                 |             |                 |
| Female                                        | 1        |                 | 1           |                 |
| Male                                          | 3.72     | (1.46-9.46)     | 3.12        | (1.19-8.16)     |
| Age groups                                    |          |                 |             |                 |
| <31 years old                                 | 1        |                 | 1           |                 |
| 31-38 years old                               | 1.34     | (0.93-1.93)     | 1.28        | (0.87-1.88)     |
| 38-47 years old                               | 2.13     | (1.49-3.04)     | 2.08        | (1.41-3.05)     |
| >47 years old                                 | 3.93     | (2.67-5.80)     | 3.90        | (2.56-5.93)     |
| Nationality                                   |          |                 |             |                 |
| Spain- developed countries                    | 1        |                 | 1           |                 |
| Latin America                                 | 0.82     | (0.58-1.16)     | 1.35        | (0.91-1.99)     |
| Maghreb and Sub-Saharan Africa                 | 1.55     | (0.95-2.53)     | 2.69        | (1.59-4.55)     |
| Eastern Europe and Middle East                 | 1.44     | (0.87-2.41)     | 2.13        | (1.24-3.69)     |
| Smoking                                       |          |                 |             |                 |
| No                                            | 1        |                 | 1           |                 |
| Yes                                           | 1.16     | (0.86-1.56)     | 1.09        | (0.77-1.54)     |
| On methadone                                   |          |                 |             |                 |
| No                                            | 1        |                 | 1           |                 |
| Yes                                           | 1.92     | (1.28-2.86)     | 1.34        | (0.83-2.17)     |
| On chronic psychotropic treatment              |          |                 |             |                 |
| No                                            | 1        |                 | 1           |                 |
| Yes                                           | 1.40     | (1.08-1.82)     | 1.15        | (0.84-1.59)     |
| HIV infection                                 |          |                 |             |                 |
| No                                            | 1        |                 | 1           |                 |
| Yes                                           | 1.24     | (0.70-2.19)     | 0.52        | (0.27-1.02)     |
| Active or past HCV infection                   |          |                 |             |                 |
| No                                            | 1        |                 | 1           |                 |
| Yes                                           | 2.62     | (1.80-3.81)     | 1.96        | (1.22-3.16)     |
| Severe mental disorder                        |          |                 |             |                 |
| No                                            | 1        |                 | 1           |                 |
| Yes                                           | 1.11     | (0.59-2.08)     | 0.87        | (0.44-1.73)     |

Note. 95\%CI: confidence interval; OR: odds ratio.
The association between LTI and HCV had been previously noted by a case-control study on inmates in the USA\(^{13}\), despite the fact that other studies have been unable to reach that same conclusion\(^{12}\). Our result could be due to the fact that HCV infection in the correctional setting is associated to intravenous drug use, and thus to socially disadvantaged populations who are traditionally at higher risk of LTI.

As for HIV, we have found a higher frequency of LTI among individuals with HIV infection. Nevertheless, multivariate analysis shows an OR of 0.52 with a CI including the null value. Therefore this result should be carefully considered since it could be influenced by other factors, such as the possibility of PPD false negative results.

Last, the percentage of individuals with LTI who had completed or were under chemoprophylactic treatment was 30.3%. That proportion is low and its below the data of 48% pointed out by a study conducted in 1999 on the Spanish inmate population\(^{22}\). Our study has not taken into account the reasons why a high proportion of inmates have not completed that treatment (refusal or abandon, medical contraindication or lack of prescription).

**CONCLUSIONS**

The prevalence of LTI in today’s Spanish inmate population is still high, being above that of the general population. In penitentiary facilities, LTI is associated to male gender, an older age, and the origin from countries where TB is endemic, being age the variable most strongly associated. Among the rest of variables under study, only HCV infection acts as a predictor for LTI. These results reinforce the relevance of LTI screening in prisons, especially among those groups with more risk factors; and they suggest that further effort should be made in prescribing and completing chemoprophylactic treatment, as measures needed to reduce the development of TB disease and prevent its transmission.

**CORRESPONDENCE**

Maite Estíbaliz López de Goicoechea Saiz
Centro Penitenciario Madrid VI
Ctra. N-400, km28
28300 Aranjuez - Madrid (Spain)
E-mail: mlopezsa3@gmail.com

**BIBLIOGRAPHIC REFERENCES**

1. World Health Organization. Global tuberculosis report. 2017. Available from: http://www.who.int/tb/publications/global_report/en/
2. Young KH, Ehman M, Reves R, Peterson Maddox BL, Khan A, Chorba TL, et al. Tuberculosis Contact Investigations – United States, 2003-2012. MMWR Morb Mortal Wkly Rep 2016;64(50-51):1369-74.
3. Nogueira P, Abrahão R, Galesi V. Tuberculosis and latent tuberculosis in prison inmates. Rev Saúde Pública 2012;46:119-27.
4. Kamarulzaman A, Reid SE, Schwitters A, Wiesing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388(10049):1115-26.
5. Rueda ZV, Arroyave L, Marin D, Lopez L, Keynan Y, Giraldo MR, et al. High prevalence and risk factors associated with latent tuberculous infection in two Colombian prisons. Int J Tuberc Lung Dis. 2014;18(10):1166-71.
6. O’Grady J, Maeurer M, Arun R, Abubakar I, Mwaba P, Bates M, et al. Tuberculosis in prisons: anatomy of global neglect. Eur Respir J. 2011;38(4):752-4.
7. Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis incidence in prisons: a systematic review. PLoS Med. 2010;7(12):e1000381.
8. Secretaría General de Instituciones Penitenciarias. Subdirección General de Coordinación de Sanidad Penitenciaria. Casos de tuberculosis en Instituciones Penitenciarias. 2013. Available from: www.institucionpenitenciaria.es/web/.../Tuberculosis_en_IIPP_2013.pdf
9. Secretaría General de Instituciones Penitenciarias. Coordinación de Sanidad Penitenciaria. Programa de Prevención y Control de Tuberculosis en el Medio Penitenciario. 3ª ed. 2011. Available from: http://www.institucionpenitenciaria.es/web/export/sites/default/datos/descargables/publicaciones/Programa_de_Prevencion_y_Control_de_la_Tuberculosis.pdf
10. Barrios-Payan JA, Castanon-Arreola M, Flores-Valdez MA, Hernandez-Pando R. Biological, clinical and epidemiological aspects of latent tuberculosis. Salud Publica Mex. 2010;52(1):70-8.
11. Gómez Rodríguez F, Bernal Bermúdez J, García Egido A. Evaluación y tratamiento de la tuberculosis latente en el adulto. Med Clin. 2001;117(3):111-4.
12. García-Guerrero J, Marco Mourino A, Sáiz de la Hoya Zamácola P, Vera-Remartínez FJ; Grupo de
estudio PREVALHEP de prisiones. Estudio multicéntrico de prevalencia de infección tuberculosa latente en los internados en prisiones españolas. Rev Esp Sanidad Penit. 2010;12(3):79-85.

13. Weant TE, Turner AN, Murphy-Weiss M, Murray DM, Wang SH. Can social history variables predict prison inmates’ risk for latent tuberculosis infection? Tuberc Res Treat. 2012;2012:132406.

14. Foster R, Ferguson TW, Rigatto C, Lerner B, Tangri N, Komenda P. A retrospective review of the two-step tuberculin skin test in dialysis patients. Can J Kidney Health Dis. 2016;3:28-016-0119-4. eCollection 2016.

15. Mamani M, Mahmudian H, Majzoobi MM, Poorolajal J. Prevalence and incidence rates of latent tuberculous infection in a large prison in Iran. Int J Tuberc Lung Dis. 2016;20(8):1072-7.

16. Dara M, Grzemaska M, Kimberling M, Reyes H, Zagorskiy A. Guidelines for control of tuberculosis in prisons. United States Agency for International Development. 2009. Available from: http://pdf.usaid.gov/pdf_docs/PNADP462.pdf

17. DiNardo AR, Guy E. Reactivation tuberculosis: role of surveillance. Expert Rev Anti Infect Ther. 2016;14(5):501-9.

18. Marco A, Sole N, Orcau A, Escribano M, del Bano L, Quintero S, et al. Prevalence of latent tuberculosis infection in inmates recently incarcerated in a men’s prison in Barcelona. Int J Tuberc Lung Dis. 2012;16(1):60-4.

19. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5:e10.

20. Arias Guillén M. Avances en el diagnóstico de la infección tuberculosa. Arch Bronconeumol. 2011;47:521-30.

21. Sole N, Marco A, Escribano M, Orcau A, Quintero S, Del Bano L, et al. Prevalence of latent tuberculosis infection amongst immigrants entering prison. Rev Esp Sanid Penit. 2012;14(1):12-8.

22. Martín V, Brugos M, Valcarcel I. Prevalencia de tratamiento de la infección tuberculosa en una prisión provincial. Rev Esp Salud Publica. 2000;74(4):361-6.

23. Alcaide Megias J, Altet Gomez MN, Canelasoler J, Pina Gutierrez JM, Mila Auge C, de Souza Galvao ML, et al. A study of the tuberculous infection in adults. Rev Clin Esp. 2003;203(7):321-8.